# EDGAR Filing Document

**Accession Number:** 0001069899
**File Stem:** 0001558370-23-001038
**Filing Date:** 2023-2
**Character Count:** 36600
**Document Hash:** bdfcc84043f0ab78d3f7dbfeb24e8805
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-001038.hdr.sgml**: 20230208

**ACCESSION NUMBER**: 0001558370-23-001038

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230208

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230208

**DATE AS OF CHANGE**: 20230208

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PHIBRO ANIMAL HEALTH CORP
- **CENTRAL INDEX KEY:** 0001069899
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 131840497
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36410
- **FILM NUMBER:** 23599693

**BUSINESS ADDRESS:**
- **STREET 1:** GLENPOINTE CENTRE EAST, 3RD FLOOR
- **STREET 2:** 300 FRANK W. BURR BLVD., SUITE 21
- **CITY:** TEANECK
- **STATE:** NJ
- **ZIP:** 07666
- **BUSINESS PHONE:** 201-329-7300

**MAIL ADDRESS:**
- **STREET 1:** GLENPOINTE CENTRE EAST, 3RD FLOOR
- **STREET 2:** 300 FRANK W. BURR BLVD., SUITE 21
- **CITY:** TEANECK
- **STATE:** NJ
- **ZIP:** 07666

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PHILIPP BROTHERS CHEMICALS INC
- **DATE OF NAME CHANGE:** 19980908

?xml version='1.0' encoding='UTF-8'?

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): February 8, 2023

**Phibro Animal Health Corporation**

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**001-36410** | &nbsp;&nbsp;**13-1840497** |
| &nbsp;&nbsp;**(State or other jurisdiction of**<br>**incorporation)** | &nbsp;&nbsp;**(Commission File Number)** | &nbsp;&nbsp;**(IRS Employer Identification No.)** |

---

**Glenpointe Centre East, 3rd Floor**

**300 Frank W. Burr Boulevard, Suite 21**

**Teaneck, New Jersey 07666-6712**

**(Address of Principal Executive Offices, including Zip Code)**

**(201) 329-7300**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Class A Common Stock, $0.0001 par value per share** | **PAHC** | **NASDAQ Stock Market** |

---

Check the appropriate box below if this Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### ITEM 2.02&nbsp;&nbsp;&nbsp;&nbsp; RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On February 8, 2023, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

#### ITEM 9.01&nbsp;&nbsp;&nbsp;&nbsp; FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 99.1 | [Press Release, dated February 8, 2023.](pahc-20230208xex99d1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | PHIBRO ANIMAL HEALTH CORPORATION <br>Registrant | PHIBRO ANIMAL HEALTH CORPORATION <br>Registrant |
| Date: February 8, 2023 |  |  |
|  | By:  | /s/ Thomas G. Dagger |
|  | Name: | Thomas G. Dagger |
|  | Title: | Senior Vice President, General Counsel and Corporate Secretary |

---

## Exhibit 99.1

![Graphic](pahc-20230208xex99d1001.jpg)

**Exhibit 99.1**

**For Immediate Release**

**Phibro Animal Health Corporation Reports Second Quarter Results**

**TEANECK, N.J., February 8, 2023 (Business Wire)** – Phibro Animal Health Corporation (Nasdaq: PAHC) ("Phibro" or the "Company") today announced financial results for its second quarter ended December 31, 2022.

Highlights for the three months ended December 31, 2022 (compared to the three months ended December 31, 2021)

-Net sales of $244.6 million, an increase of $11.9 million, or 5%

-Net income of $7.2 million, a decrease of $10.3 million, or 59%

-Diluted EPS of $0.18, a decrease of $0.25, or 59%

-Adjusted EBITDA of $30.9 million, an increase of $1.8 million, or 6%

-Adjusted net income of $13.8 million, a decrease of $1.3 million, or 9%

-Adjusted diluted EPS of $0.34, a decrease of $0.03, or 9%

COMMENTARY

"We were pleased with our second quarter performance. In our core business segment, Animal Health, we reported our seventh consecutive quarter of year-over-year sales growth in each of our three major product categories. On a calendar-year basis, this translates into sales growth of more than 20% in 2022 over 2020, which relative to some industry reports, puts us in the top tier of animal health companies," said Jack Bendheim, Phibro's Chairman, President, and Chief Executive Officer.

Jack continued, "We are excited to have Alejandro Bernal join our Board of Directors. We welcome his insights and believe they will be particularly impactful with respect to our companion animal business, which we seek to meaningfully grow over the coming years as we continue to focus on progressing our pipeline of projects in development."

QUARTERLY RESULTS

**Net sales**

Net sales of $244.6 million for the three months ended December 31, 2022, increased $11.9 million, or 5%, as compared to the three months ended December 31, 2021. Animal Health and Performance Products increased $12.9 million and $4.1 million, respectively. Mineral Nutrition decreased $5.0 million.

*Animal Health*

Net sales of $163.8 million for the three months ended December 31, 2022, increased $12.9 million, or 9%. Net sales of MFAs and other increased $5.5 million, or 6%, due to increased demand for our MFAs in Latin America and for processing aids used in the ethanol fermentation industry. Net sales of nutritional specialty products increased $6.5 million, or 17%, due mostly to higher domestic demand and higher average selling prices for dairy products, along with growth in the companion animal product. Net sales of vaccines increased $0.9 million, or 4%, due to increased demand.

------

![Graphic](pahc-20230208xex99d1001.jpg)

*Mineral Nutrition*

Net sales of $61.6 million for the three months ended December 31, 2022, decreased $5.0 million, or 8%, driven by a decrease in demand for trace minerals, partially offset by higher average selling prices. The increase in average selling prices is correlated to the movement of the underlying raw material costs.

*Performance Products*

**Net sales of $19.2 million for the three months ended December 31, 2022, increased $4.1 million, or 27%, primarily as a result of increased demand for copper-based products and higher average selling prices for copper-based products and ingredients for personal care products.**

#### Gross profit
Gross profit of $77.4 million for the three months ended December 31, 2022, increased $6.7 million, or 9%, as compared to the three months ended December 31, 2021. Gross margin increased 120 basis points to 31.6% of net sales for the three months ended December 31, 2022, as compared to 30.4% for the three months ended December 31, 2021, due to favorable product and geographical mix and lower production costs.

Animal Health gross profit increased $6.3 million, primarily driven by higher sales volumes and favorable production costs. Mineral Nutrition gross profit decreased $1.1 million, driven primarily by lower sales volume and an increase in raw material costs. Performance Products gross profit increased $1.5 million as a result of increased demand and higher average selling prices for copper-based products.

**Selling, general and administrative expenses**

Selling, general and administrative expenses ("SG&A") of $61.5 million for the three months ended December 31, 2022, increased $13.2 million, or 27%, as compared to the three months ended December 31, 2021. SG&A for the three months ended December 31, 2022, included $6.6 million of environmental remediation costs. The majority of these environmental remediation costs relate to a tentative settlement we have reached in a lawsuit concerning alleged historical environmental contamination from a facility in California we acquired years ago within our Performance Products segment. SG&A for the three months ended December 31, 2021, included a $1.2 million gain on sale of investment. Excluding the environmental remediation costs and the gain on sale of investment, SG&A increased $5.4 million, or 11%.

Animal Health SG&A increased $3.4 million, primarily due to an increase in employee-related and other miscellaneous costs. Mineral Nutrition SG&A was comparable to prior year. Performance Products SG&A increased $0.5 million. Corporate costs increased by $1.4 million, driven by net changes in costs related to employees and strategic investments.

**Interest expense, net**

Interest expense, net of $3.9 million for the three months ended December 31, 2022, increased by $0.9 million, as compared to the three months ended December 31, 2021, due to increased debt outstanding, partially offset by an increase in interest income and lower average fixed rates in our interest rate swap agreement.

**Foreign currency gains, net**

Foreign currency gains, net for the three months ended December 31, 2022, were $0.1 million, as compared to $4.2 million of net gains for the three months ended December 31, 2021. Prior period gains were driven by the weakening of certain currencies relative to the U.S. dollar.

**Provision for income taxes**

The provision for income taxes was $4.9 million and $6.1 million for the three months ended December 31, 2022 and 2021, respectively. The effective income tax rate was 40.5% and 25.8% for the three months ended December 31, 2022 and 2021,

------

![Graphic](pahc-20230208xex99d1001.jpg)

respectively. The current provision for income taxes was impacted by the final foreign tax credit regulations that were in effect during the three months ended December 31, 2022, in addition to losses generated in international jurisdictions where no tax benefit is being recognized.

**Net income**

Net income of $7.2 million for the three months ended December 31, 2022, decreased $10.3 million, as compared to net income of $17.5 million for the three months ended December 31, 2021. Operating income decreased $6.5 million, driven by higher SG&A, partially offset by favorable gross profit. Excluding the $6.6 million environmental remediation costs, operating income would have increased $0.1 million. The increase in gross profit was due to higher product demand and higher selling prices. Interest expense, net increased $0.9 million and foreign currency gains, net decreased $4.0 million. Income tax expense decreased by $1.2 million.

**Adjusted EBITDA**

Adjusted EBITDA of $30.9 million for the three months ended December 31, 2022, increased $1.8 million, as compared to the three months ended December 31, 2021. Animal Health Adjusted EBITDA increased $3.4 million due to higher gross profit margin, partially offset by higher SG&A. Performance Products Adjusted EBITDA increased $1.0 million due to higher gross profit, also partially offset by higher SG&A. Mineral Nutrition Adjusted EBITDA decreased $1.1 million, driven by lower gross profit. Corporate expenses increased $1.4 million, driven by increased costs related to employees and strategic investments.

**Adjusted provision for income taxes**

The adjusted effective income tax rates for the three months ended December 31, 2022 and 2021, were 34.3% and 25.5%, respectively. The increase in our adjusted effective income tax rate was driven by changes in the final foreign tax credit regulations that went into effect on July 1, 2022, in addition to losses generated in international jurisdictions where no tax benefit is being recognized.

**Adjusted Net Income**

Adjusted net income of $13.8 million for the three months ended December 31, 2022, decreased $1.3 million, or 9%, as compared to the prior year. The decrease was driven by higher SG&A and a higher tax provision, offset by higher gross profit. The increase in gross profit resulted from higher sales, partially offset by higher raw material and production costs. SG&A expenses increased due to net changes in costs related to employee and employee-related costs and an increase in strategic investments.

**Adjusted diluted EPS**

Adjusted diluted EPS was $0.34 for the quarter, a decrease of $0.03, or 9%, as compared to $0.37 in the prior year.

**BALANCE SHEET AND CASH FLOWS**

● Free cash flow was $(45) million <sup>(1)</sup> for the twelve months ended December 31, 2022

● 4.2x gross leverage ratio as of December 31, 2022

-$477 million total debt

-$113 million Adjusted EBITDA for the twelve months ended December 31, 2022

● Liquidity of $202 million, consisting of $78 million of cash and short-term investments on hand and $124 million of available revolving credit (subject to leverage ratio limitations) as of December 31, 2022

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Free cash flow equals cash flow from operating activities less capital expenditures for the trailing 12-months ended December 31, 2022, and excluded a $15 million purchase of property financed in part by a secured term loan during the quarter ended September 30, 2022, included within capital expenditures in the Consolidated Statements of Cash Flows, included in Item 1 of our most recent Quarterly Report on Form 10-Q.

------

![Graphic](pahc-20230208xex99d1001.jpg)

The $(45) million in free cash flow for the twelve months ended December 31, 2022, is driven primarily by a $58 million increase in inventory over the same period, representing approximately one month of additional inventory on hand intended to mitigate the risk of supply chain disruptions impacting the Company's ability to fulfill customer orders on a timely basis.

**FISCAL YEAR 2023 FINANCIAL GUIDANCE**

The Company updated guidance for GAAP Net Income and Diluted EPS primarily to reflect the unfavorable impact of non-operational environmental remediation costs recorded in the quarter ended December 31, 2022, but reiterated guidance for other financial metrics as detailed below.

Financial guidance for the year ending June 30, 2023, is as follows:

● Net sales of $960 million - $1 billion (unchanged)

● Net income of $34 - $38 million, from $39 - $43 million

● Diluted EPS of $0.84 - $0.94, from $0.96 - $1.06

● Adjusted EBITDA of $113 - $118 million (unchanged)

● Adjusted net income of $49 - $53 million (unchanged)

● Adjusted diluted EPS of $1.21 - $1.31 (unchanged)

● Adjusted effective tax rate of 33% (unchanged)

Guidance for GAAP measures assumes actual foreign exchange losses for the six months ended December 31, 2022, and the Company's projected foreign exchanges rates for the six months ending June 30, 2023.

WEBCAST & CONFERENCE CALL DETAILS

Phibro Animal Health Corporation will host a webcast and conference call during which the Company will review its financial results and respond to questions.

Date: Thursday, February 9, 2023

Time: 9:00 AM Eastern

Location: <u>https://investors.pahc.com</u>

U.S. Toll-Free: +1 (888) 330-2022

International Toll: +1 (365) 977-0051

---

| | |
|:---|:---|
| Conference ID: | **3927884** |

---

NOTE: To join this conference call, all participants will be required to provide the Conference ID number.

A replay of the webcast will be archived and made available on Phibro's website.

<u>DISCLOSURE NOTICES</u>

*Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "aim," "anticipate," "believe," "estimate," "expect," "forecast," "outlook," "potential," "project," "projection," "plan," "intend," "seek," "may," "could," "would," "will," "should," "can," "can have," "likely," the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions* 

------

![Graphic](pahc-20230208xex99d1001.jpg)

*prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned "Forward-Looking Statements" and "Risk Factors." These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.*

*Non-GAAP Financial Information: We use non-GAAP financial measures, such as adjusted EBITDA, adjusted net income, adjusted diluted EPS and free cash flow to assess and analyze our operational results and trends and to make financial and operational decisions. Management uses adjusted EBITDA as its primary operating measure. We report adjusted net income to portray the results of our operations prior to considering certain income statement elements. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this communication should not be considered alternatives to measurements required by GAAP, such as net income, operating income and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this communication and/or our Quarterly Report on Form 10-Q and Annual Report on Form 10-K.* 

*We are not providing a reconciliation of forward-looking guidance of non-GAAP financial measures to the most directly comparable GAAP financial measures because of the uncertainty regarding, and the potential variability of, certain of the items required for a reconciliation; accordingly, a reconciliation of the non-GAAP financial measure to the corresponding GAAP financial measure is not available without unreasonable effort.* 

*Internet Posting of Information: We routinely post information that may be important to investors in the "Investors" section of our website at www.pahc.com. We encourage investors and potential investors to consult our website regularly for important information about us.*

------

![Graphic](pahc-20230208xex99d1001.jpg)

**Phibro Animal Health Corporation**

**Consolidated Results of Operations**

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months** | **Three Months** | **Three Months** | **Three Months** | **Three Months** | **Six Months**  | **Six Months**  | **Six Months**  | **Six Months**  | **Six Months**  |  |
| **For the Periods Ended December 31** | **2022** | **2021** | **Change** | **Change** | **Change** | **2022** | **2021** | **Change** | **Change** | **Change** |  |
|  | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** |  |
| Net sales | $244.6 | $232.7 | $11.9 |  | *5*<br>*%*  | $477.2 | $447.4 | $29.8 |  | *7* | *%* |
| Cost of goods sold | 167.3 | 162.0 | 5.2 |  | *3*<br>*%*  | 331.1 | 312.0 | 19.1 |  | *6* | *%* |
| &nbsp;&nbsp;Gross profit | 77.4 | 70.7 | 6.7 |  | *9*<br>*%*  | 146.0 | 135.4 | 10.7 |  | *8* | *%* |
| Selling, general and administrative | 61.5 | 48.4 | 13.2 |  | *27*<br>*%*  | 116.5 | 98.4 | 18.1 |  | *18* | *%* |
| &nbsp;&nbsp;Operating income | 15.8 | 22.3 | (6.5) |  | *(29)*<br>*%*  | 29.5 | 36.9 | (7.4) |  | *(20)* | *%* |
| Interest expense, net | 3.9 | 3.0 | 0.9 |  | *32*<br>*%*  | 7.0 | 5.8 | 1.1 |  | *19* | *%* |
| Foreign currency (gains) losses, net | (0.1) | (4.2) | 4.0 |  | *\** | 5.1 | (2.1) | 7.1 |  | *\** |  |
| &nbsp;&nbsp;Income before income taxes | 12.1 | 23.5 | (11.4) |  | *(49)*<br>*%*  | 17.5 | 33.1 | (15.6) |  | *(47)* | *%* |
| Provision for income taxes | 4.9 | 6.1 | (1.2) |  | *(19)*<br>*%*  | 6.5 | 9.1 | (2.7) |  | *(29)* | *%* |
| &nbsp;&nbsp;Net income | $7.2 | $17.5 | $(10.3) |  | *(59)*<br>*%*  | $11.1 | $24.0 | $(12.9) |  | *(54)* | *%* |
| Net income per share - basic and diluted | $0.18 | $0.43 | $(0.25) |  | *(59)*<br>*%*  | $0.27 | $0.59 | $(0.32) |  | *(54)* | *%* |
| Weighted average common shares outstanding |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;basic and diluted | 40.5 | 40.5 |  |  |  | 40.5 | 40.5 |  |  |  |  |
| Ratio to net sales |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Gross profit | *31.6%* | *30.4%* |  |  |  | *30.6%* | *30.3%* |  |  |  |  |
| &nbsp;&nbsp;Selling, general and administrative | *25.2%* | *20.8%* |  |  |  | *24.4%* | *22.0%* |  |  |  |  |
| &nbsp;&nbsp;Operating income | *6.5%* | *9.6%* |  |  |  | *6.2%* | *8.2%* |  |  |  |  |
| &nbsp;&nbsp;Income before income taxes | *4.9%* | *10.1%* |  |  |  | *3.7%* | *7.4%* |  |  |  |  |
| &nbsp;&nbsp;Net income | *2.9%* | *7.5%* |  |  |  | *2.3%* | *5.4%* |  |  |  |  |
| Effective tax rate | *40.5%* | *25.8%* |  |  |  | *36.9%* | *27.6%* |  |  |  |  |

---

Amounts and percentages may reflect rounding adjustments

\*Calculation not meaningful

------

![Graphic](pahc-20230208xex99d1001.jpg)

**Phibro Animal Health Corporation**

**Segment Net Sales and Adjusted EBITDA**

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months** | **Three Months** | **Three Months** | **Three Months** | **Three Months** |  | **Six Months**  | **Six Months**  | **Six Months**  | **Six Months**  |  |
| **For the Periods Ended December 31** | **2022** | **2021** | **Change** | **Change** | **Change** |  | **2022** | **2021** | **Change** | **Change** |  |
|  | ***(in millions, except percentages)*** | ***(in millions, except percentages)*** | ***(in millions, except percentages)*** | ***(in millions, except percentages)*** | ***(in millions, except percentages)*** | ***(in millions, except percentages)*** | ***(in millions, except percentages)*** | ***(in millions, except percentages)*** | ***(in millions, except percentages)*** | ***(in millions, except percentages)*** |  |
| **Net Sales** |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;MFAs and other | $97.2 | $91.7 | $5.5 |  | *6* | *%* | $190.0 | $175.5 | $14.5 | *8* | *%* |
| &nbsp;&nbsp;Nutritional specialties | 43.9 | 37.3 | 6.5 |  | *17* | *%* | 82.9 | 73.3 | 9.6 | *13* | *%* |
| &nbsp;&nbsp;Vaccines | 22.8 | 21.9 | 0.9 |  | *4* | *%* | 45.8 | 43.1 | 2.7 | *6* | *%* |
| Animal Health | 163.8 | 150.9 | 12.9 |  | *9* | *%* | 318.7 | 291.9 | 26.7 | *9* | *%* |
| Mineral Nutrition | 61.6 | 66.7 | (5.0) |  | *(8)* | *%* | 121.3 | 121.1 | 0.2 | *0* | *%* |
| Performance Products | 19.2 | 15.1 | 4.1 |  | *27* | *%* | 37.2 | 34.4 | 2.9 | *8* | *%* |
| Total | $244.6 | $232.7 | $11.9 |  | *5* | *%* | $477.2 | $447.4 | $29.8 | *7* | *%* |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Adjusted EBITDA** |  |  |  |  |  |  |  |  |  |  |  |
| Animal Health | $37.1 | $33.7 | $3.4 |  | *10* | *%* | $64.0 | $61.3 | $2.7 | *4* | *%* |
| Mineral Nutrition | 4.4 | 5.5 | (1.1) |  | *(20)* | *%* | 9.7 | 10.1 | (0.4) | *(4)* | *%* |
| Performance Products | 2.3 | 1.3 | 1.0 |  | *73* | *%* | 4.7 | 3.5 | 1.2 | *34* | *%* |
| Corporate | (12.8) | (11.5) | (1.4) |  | *12* | *%* | (25.3) | (23.3) | (2.0) | *9* | *%* |
| Total | $30.9 | $29.1 | $1.8 |  | *6* | *%* | $53.0 | $51.6 | $1.5 | *3* | *%* |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Ratio to segment net sales |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Animal Health | *22.6*<br>*%*  | *22.3*<br>*%*  |  |  |  |  | *20.1*<br>*%*  | *21.0*<br>*%*  |  |  |  |
| &nbsp;&nbsp;Mineral Nutrition | *7.1*<br>*%*  | *8.3*<br>*%*  |  |  |  |  | *8.0*<br>*%*  | *8.3*<br>*%*  |  |  |  |
| &nbsp;&nbsp;Performance Products | *11.9*<br>*%*  | *8.8*<br>*%*  |  |  |  |  | *12.5*<br>*%*  | *10.1*<br>*%*  |  |  |  |
| &nbsp;&nbsp;Corporate <sup>(1)</sup> | *(5.2)*<br>*%*  | *(4.9)*<br>*%*  |  |  |  |  | *(5.3)*<br>*%*  | *(5.2)*<br>*%*  |  |  |  |
| &nbsp;&nbsp;Total <sup>(1)</sup> | *12.6*<br>*%*  | *12.5*<br>*%*  |  |  |  |  | *11.1*<br>*%*  | *11.5*<br>*%*  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Reconciliation of GAAP Net Income to Adjusted EBITDA** |  |  |  |  |  |  |  |  |  |  |  |
| Net income | $7.2 | $17.5 | $(10.3) |  | *(59)* | *%* | $11.1 | $24.0 | $(12.9) | *(54)* | *%* |
| &nbsp;&nbsp;Interest expense, net | 3.9 | 3.0 | 0.9 |  | *32* | *%* | 7.0 | 5.8 | 1.1 | *19* | *%* |
| &nbsp;&nbsp;Provision for income taxes | 4.9 | 6.1 | (1.2) |  | *(19)* | *%* | 6.5 | 9.1 | (2.7) | *(29)* | *%* |
| &nbsp;&nbsp;Depreciation and amortization | 8.5 | 8.0 | 0.5 |  | *6* | *%* | 16.9 | 15.9 | 1.1 | *7* | *%* |
| EBITDA | 24.5 | 34.5 | (10.0) |  | *(29)* | *%* | 41.4 | 54.8 | (13.4) | *(24)* | *%* |
| &nbsp;&nbsp;Environmental remediation costs | 6.6 |  | 6.6 |  | *\** |  | 6.6 |  | 6.6 | *\** |  |
| &nbsp;&nbsp;Gain on sale of investment |  | (1.2) | 1.2 |  | *\** |  |  | (1.2) | 1.2 | *\** |  |
| &nbsp;&nbsp;Foreign currency losses, net | (0.1) | (4.2) | 4.0 |  | *\** |  | 5.1 | (2.1) | 7.1 | *\** |  |
| Adjusted EBITDA | $30.9 | $29.1 | $1.8 |  | *6* | *%* | $53.0 | $51.6 | $1.5 | *3* | *%* |

---

Amounts and percentages may reflect rounding adjustments

\* Calculation not meaningful

&nbsp;&nbsp;&nbsp;&nbsp;(1) Reflects ratio to total net sales

------

![Graphic](pahc-20230208xex99d1001.jpg)

**Phibro Animal Health Corporation**

**Adjusted Net Income**

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months** | **Three Months** | **Three Months** | **Three Months** | **Three Months** | **Six Months**  | **Six Months**  | **Six Months**  | **Six Months**  | **Six Months**  |  |
| **For the Periods Ended December 31** | **2022** | **2021** | **Change** | **Change** | **Change** | **2022** | **2021** | **Change** | **Change** | **Change** |  |
|  | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** | ***(in millions, except per share amounts and percentages)*** |  |
| **Reconciliation of GAAP Net Income to Adjusted Net Income** |  |  |  |  |  |  |  |  |  |  |  |
| Net income | $7.2 | $17.5 | $(10.3) |  | *(59)*<br>*%*  | $11.1 | $24.0 | $(12.9) |  | *(54)* | *%* |
| Acquisition-related intangible amortization<sup>(1)</sup> | 1.7 | 1.4 | 0.3 |  | *19*<br>*%*  | 3.3 | 2.9 | 0.4 |  | *15* | *%* |
| Acquisition-related intangible amortization<sup>(2)</sup> | 0.8 | 0.7 | 0.0 |  | *6*<br>*%*  | 1.5 | 1.4 | 0.1 |  | *9* | *%* |
| Environmental remediation costs<sup>(2)</sup> | 6.6 |  | 6.6 |  | *\** | 6.6 |  | 6.6 |  | *\** |  |
| Gain on sale of investment<sup>(2)</sup> |  | (1.2) | 1.2 |  | *\** |  | (1.2) | 1.2 |  | *\** |  |
| Foreign currency (gains) losses, net<sup>(3)</sup> | (0.1) | (4.2) | 4.0 |  | *\** | 5.1 | (2.1) | 7.1 |  | *\** |  |
| Adjustments to income taxes<sup>(4)</sup> | (2.3) | 0.9 | (3.2) |  | *\** | (5.4) | 0.3 | (5.7) |  | *\** |  |
| Adjusted net income | $13.8 | $15.1 | $(1.3) |  | *(9)*<br>*%*  | $22.1 | $25.3 | $(3.2) |  | *(13)* | *%* |
| **Statement of Operations Line Items - adjusted** |  |  |  |  |  |  |  |  |  |  |  |
| Adjusted cost of goods sold<sup>(1)</sup> | $165.6 | $160.6 | $5.0 |  | *3*<br>*%*  | $327.8 | $309.2 | $18.7 |  | *6* | *%* |
| &nbsp;&nbsp;Adjusted gross profit | 79.0 | 72.1 | 7.0 |  | *10*<br>*%*  | 149.4 | 138.2 | 11.1 |  | *8* | *%* |
| Adjusted selling, general and administrative<sup>(2)</sup> | 54.2 | 48.8 | 5.3 |  | *11*<br>*%*  | 108.4 | 98.3 | 10.2 |  | *10* | *%* |
| Adjusted interest expense, net | 3.9 | 3.0 | 0.9 |  | *32*<br>*%*  | 7.0 | 5.8 | 1.1 |  | *19* | *%* |
| &nbsp;&nbsp;Adjusted income before income taxes | 21.0 | 20.3 | 0.7 |  | *3*<br>*%*  | 34.0 | 34.1 | (0.1) |  | *(0)* | *%* |
| Adjusted provision for income taxes<sup>(4)</sup> | 7.2 | 5.2 | 2.0 |  | *39*<br>*%*  | 11.9 | 8.8 | 3.0 |  | *34* | *%* |
| &nbsp;&nbsp;Adjusted net income | $13.8 | $15.1 | $(1.3) |  | *(9)*<br>*%*  | $22.1 | $25.3 | $(3.2) |  | *(13)* | *%* |
| Adjusted net income per share |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;diluted | $0.34 | $0.37 | $(0.03) |  | *(9)*<br>*%*  | $0.55 | $0.62 | $(0.07) |  | *(13)* | *%* |
| Weighted average common shares outstanding |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;diluted | 40.5 | 40.5 |  |  |  | 40.5 | 40.5 |  |  |  |  |
| Ratio to net sales |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Adjusted gross profit | *32.3*<br>*%*  | *31.0*<br>*%*  |  |  |  | *31.3*<br>*%*  | *30.9*<br>*%*  |  |  |  |  |
| &nbsp;&nbsp;Adjusted selling, general and administrative | *22.2*<br>*%*  | *21.0*<br>*%*  |  |  |  | *22.7*<br>*%*  | *22.0*<br>*%*  |  |  |  |  |
| &nbsp;&nbsp;Adjusted income before income taxes | *8.6*<br>*%*  | *8.7*<br>*%*  |  |  |  | *7.1*<br>*%*  | *7.6*<br>*%*  |  |  |  |  |
| &nbsp;&nbsp;Adjusted net income | *5.6*<br>*%*  | *6.5*<br>*%*  |  |  |  | *4.6*<br>*%*  | *5.7*<br>*%*  |  |  |  |  |
| Adjusted effective tax rate | *34.3*<br>*%*  | *25.5*<br>*%*  |  |  |  | *34.9*<br>*%*  | *25.9*<br>*%*  |  |  |  |  |

---

Amounts and percentages may reflect rounding adjustments

\* Calculation not meaningful

<sup>(1)</sup> Adjusted cost of goods sold excludes acquisition-related intangible amortization

<sup>(2)</sup> Adjusted selling, general and administrative excludes acquisition-related intangible amortization, environmental remediation costs, and gain on sale of investment

<sup>(3)</sup> Foreign currency losses, net are excluded from adjusted net income

<sup>(4)</sup> Adjusted provision for income taxes excludes the income tax effect of pre-tax income adjustments and certain income tax items

------

![Graphic](pahc-20230208xex99d1001.jpg)

**Phibro Animal Health Corporation**

**Operating, Investing and Free Cash Flows**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months** | **Three Months** | **Three Months** | **Six Months**  | **Six Months**  | **Six Months**  |
| <br>**For the Periods Ended December 31** | **2022** | **2021** | **Change** | **2022** | **2021** | **Change** |
|  | ***(in millions)*** | ***(in millions)*** | ***(in millions)*** | ***(in millions)*** | ***(in millions)*** | ***(in millions)*** |
| EBITDA | $24.5 | $34.5 | $(10.0) | $41.4 | $54.8 | $(13.4) |
| Adjustments |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Environmental remediation costs | 6.6 |  | 6.6 | 6.6 |  | 6.6 |
| &nbsp;&nbsp;Gain on sale of investment |  | (1.2) | 1.2 |  | (1.2) | 1.2 |
| &nbsp;&nbsp;Foreign currency (gains) losses, net | (0.1) | (4.2) | 4.0 | 5.1 | (2.1) | 7.1 |
| Interest paid, net | (3.7) | (2.8) | (0.9) | (6.6) | (5.5) | (1.1) |
| Income taxes paid | (5.5) | (3.1) | (2.4) | (9.3) | (6.0) | (3.3) |
| Changes in operating assets and liabilities and other items | (24.2) | (3.1) | (21.1) | (50.3) | (16.1) | (34.2) |
| Net cash (used) provided by operating activities | $(2.5) | $20.1 | $(22.6) | $(13.2) | $23.9 | $(37.1) |
| Short-term investments, net | $— | $23.9 | $(23.9) | $7.0 | $10.9 | $(3.9) |
| Capital expenditures | (9.8) | (7.7) | (2.1) | (33.0) | (15.1) | (17.9) |
| Cash proceeds from the sale of investment |  | 1.4 | (1.4) |  | 1.4 | (1.4) |
| Other investing, net | 0.0 |  | 0.0 | 0.0 | (0.2) | 0.2 |
| Net cash used by investing activities  | $(9.8) | $17.6 | $(27.3) | $(26.0) | $(3.1) | $(22.9) |
| Net cash flow before financing activities | $(12.3) | $37.7 | $(50.0) | $(39.1) | $20.8 | $(60.0) |
| Free cash flow: |  |  |  |  |  |  |
| Net cash (used) provided by operating activities | $(2.5) | $20.1 | $(22.6) | $(13.2) | $23.9 | $(37.1) |
| Capital expenditures | (9.8) | (7.7) | (2.1) | (33.0) | (15.1) | (17.9) |
| Building purchase |  |  |  | 15.0 |  | 15.0 |
| Free cash flow (adjusted) | $(12.3) | $12.4 | $(24.7) | $(31.2) | $8.8 | $(40.0) |

---

Amounts and percentages may reflect rounding adjustments

------

![Graphic](pahc-20230208xex99d1001.jpg)

**About Phibro Animal Health Corporation**

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit <u>www.pahc.com</u>.

Contacts

Phibro Animal Health Corporation

Damian Finio

Chief Financial Officer

+1-201-329-7300

Or

investor.relations@pahc.com

------